Elahere (Mirvetuximab Soravtansine-Gynx) for Ovarian Cancer

Overview
Elahere is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. To be eligible to use Elahere for treatment, a person must have received one to three prior systemic treatment regimens and be confirmed FRa-positive through an FDA-approved test. Elahere is also known by its drug name, mirvetuximab soravtansine-gynx.

Elahere is an antibody-drug conjugate that targets cancer cells expressing folate receptor alpha. It consists of two parts: a biologically engineered antibody that attaches to the FRa protein on cancer cells, and a microtubule inhibitor. This combination allows the antibody to deliver the drug directly into cancer cells, where the microtubule inhibitor disrupts cell division, leading to cancer cell death.

How do I take it?
Prescribing information states that Elahere is administered as an intravenous (IV) infusion every three weeks. Before each infusion, a person is generally premedicated with corticosteroids, antihistamines, antipyretics, antiemetics, ophthalmic topical steroids, and lubricating eye drops to reduce side effects. The drug should be diluted in 5 percent dextrose and is not compatible with saline solutions. Elahere should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Elahere include increased aspartate aminotransferase, alanine aminotransferase, and increased alkaline phosphatase (types of liver enzymes), diarrhea, fatigue, blurred vision, nausea, abdominal pain, keratopathy (a corneal disorder), peripheral neuropathy (nerve damage), musculoskeletal pain, reduced lymphocytes (a type of white blood cell), decreased platelets (cells that help blood clot), low magnesium, low hemoglobin (oxygen-carrying blood component), dry eye, constipation, reduced leukocytes (white blood cells), vomiting, low albumin (blood protein), reduced appetite, and decreased neutrophils (a type of immune cell).

Rare but serious side effects may include ocular toxicity (vision impairment, eye pain, photophobia, keratopathy, and uveitis), pneumonitis (lung inflammation), and peripheral neuropathy. Elahere may also cause embryo-fetal toxicity, meaning it can harm a fetus if taken during pregnancy.

For more information about this treatment, visit:

Label: Elahere — Mirvetuximab Soravtansine Injection, Solution — DailyMed